Wird geladen...

A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors

PURPOSE: Vorinostat (V) at levels >2.5 μM enhances chemotherapy in vitro. Yet the approved oral dose of 400 mg inconsistently achieves this level in patients. We developed an intermittent oral pulse-dose schedule of V to increase serum levels. We combined V with the cyclin dependent kinase inhibi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Dickson, Mark Andrew, Rathkopf, Dana E., Carvajal, Richard D., Grant, Steven, Roberts, John D., Reid, Joel M., Ames, Matthew M., McGovern, Renee M., Lefkowitz, Robert A., Gonen, Mithat, Cane, Lauren M., Dials, Heather J., Schwartz, Gary K.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2010
Schlagworte:
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3545439/
https://ncbi.nlm.nih.gov/pubmed/20461440
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-010-9447-x
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!